Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

Ayoub, Jean-Pierre; Audet-Lapointe, P; Méthot, Y; Hanley, James A.; Beaulieu, Raymond; Chemaly, Roy F.; Cormier, André; Déry, Johanne; Drouin, P; Gauthier, Philippe; Guay, Jean Pierre; Husson, David; Labrie, Fernand; Lambert, B.; Latreille, Jean; Mandeville, Rosemonde; Michon, Bruno; Pichet, R.; Sidrac, S.; Simard, Anne; Simard, Paulette; Stanimir, G.; Vauclair, R; Vigeant, Jacinthe

doi:10.1016/s0090-8258(88)80012-x

Cited by 35 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various hormonal agents have been used (progestins, selective estrogen receptor modulators, aromatase inhibitors, synthetic steroid derivatives, and gonadotropin-releasing (GN-RH) hormone analogs) with a response rate of 9% to 55% in different studies (Kokka et al 2010). Cochrane Database Systematic Review of hormonal therapy in advanced or recurrent endometrial cancer assessed 542 patients from 6 different randomized trials (Stolyarova I ;Rendina et al 1984;Ayoub et al 1988;Urbanski et al 1993;Thigpen et al 1999;Pandya et al 2001) (Table 8). The results indicated that hormonal therapy did not prolong overall survival or progression free survival in women with advanced or recurrent endometrial cancer (Kokka et al 2010).…”

Section: Recurrent Endometrial Cancermentioning

confidence: 99%

Treatment Strategies and Prognosis of Endometrial Cancer

Garg¹,

Mutch²

2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

Section: Recurrent Endometrial Cancermentioning

confidence: 99%

Treatment Strategies and Prognosis of Endometrial Cancer

Garg¹,

Mutch²

2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

“…A limited number of randomized trials compared two different chemotherapeutic regimens containing progestins [60,62]. In a study by Ayoub et al [63], the use of cyclophosphamide, doxorubicin, and 5-fluorouracil was compared with the same treatment plus sequential medroxyprogesterone acetate alternating with tamoxifen. In that study of 43 patients, the response rate in the hormone-containing regimen was 43%, compared with 15% in the chemotherapyonly arm [63].…”

Section: Combination Chemohormonal Therapymentioning

confidence: 99%

“…In a study by Ayoub et al [63], the use of cyclophosphamide, doxorubicin, and 5-fluorouracil was compared with the same treatment plus sequential medroxyprogesterone acetate alternating with tamoxifen. In that study of 43 patients, the response rate in the hormone-containing regimen was 43%, compared with 15% in the chemotherapyonly arm [63]. The documented median survival time for patients in the combination chemotherapy-hormone therapy arm was noted to be 14 months, compared with 11 months for the chemotherapy-only arm [49].…”

Section: Combination Chemohormonal Therapymentioning

confidence: 99%

“…The documented median survival time for patients in the combination chemotherapy-hormone therapy arm was noted to be 14 months, compared with 11 months for the chemotherapy-only arm [49]. This difference in median survival times was not statistically significant [63]. In a study by Cornelison et al [64], two groups of 50 women were treated during two different time periods.…”

Section: Combination Chemohormonal Therapymentioning

confidence: 99%

See 1 more Smart Citation

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Rauh‐Hain

Carmen

2010

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Discuss the role of radiation therapy for advanced stage endometrial cancer in order to differentiate between patients who should receive only radiation therapy and patients requiring surgery and/or chemotherapy in addition to radiation.2. Evaluate the role of surgery for stage IV and recurrent endometrial cancer in order to select patients most likely to benefit from cytoreductive surgery.3. Evaluate the role of chemotherapy, particularly in conjunction with radiotherapy, in advanced stage endometrial carcinoma and select appropriate candidates for multimodality therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTWomen with recurrent or advanced endometrial cancer constitute a heterogeneous group of patients. Depending on previous treatment, women with recurrent endometrial cancer may be appropriate candidates for surgery, radiation therapy, hormonal therapy, or chemotherapy. Women with advanced stage disease at presentation may also be appropriate candidates for systemic and local therapies. We review the treatment options available to treat recurrent and locally advanced endometrial cancer. Treatment choice depends largely on the localization of disease, the patient's performance status and previ-

show abstract

“…Phase II studies using multiagent chemotherapy in combination with progestational agents have reported response rates of approximately 50% [12, 13, 14]. However, at present, the role of combination treatment with hormones and active chemotherapeutic agents for advanced or recurrent endometrial carcinoma is not clearly defined.…”

Section: Introductionmentioning

confidence: 99%

Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study

et al. 1999

View full text Add to dashboard Cite

Twenty-three patients with advanced or recurrent endometrial carcinoma entered a prospective study of chemotherapy which consisted of carboplatin (300 mg/m²), methotrexate (30 mg/m²), and 5-fluoruracil (500 mg/m²) given on day 1, in a 3-weekly schedule, in combination with medroxyprogesterone acetate (MPA): 300 mg daily, p.o., until progression (JMF-M regimen). None had received prior chemotherapy and/or hormonotherapy for metastatic disease. Ten patients had received radiotherapy. Response to treatment was evaluated every two courses. Objective response was seen in 17 of the 23 patients (74%, 95% confidence interval = 52–90%), with 2 long-lasting complete responses (9%). The median response duration was 10+ months (3–45+). The median survival was 16+ months (2–45+). The 2 complete responders, the first in the lung and the second in groin nodes, are without evidence or recurrence after 32 and 45 months, respectively. The regimen was given on an outpatient basis and was well tolerated. The major toxic effects were myelosuppression (less than 14% leukopenia, anemia and thrombocytopenia). The MPA-related side effects were: weight gain (22%), hypertension (17%) and thromboplebitis (17%). In 2 patients, consolidation treatment with MPA was discontinued because of thromboplebitis. In conclusion, the JMF-M regimen is highly active with an acceptable toxicity in patients with recurrent or metastatic endometrial carcinoma.

show abstract

Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status

Cited by 35 publications

References 15 publications

Treatment Strategies and Prognosis of Endometrial Cancer

Treatment Strategies and Prognosis of Endometrial Cancer

Treatment for Advanced and Recurrent Endometrial Carcinoma: Combined Modalities

Carboplatin, Methotrexate and 5-Fluorouracil in Combination with Medroxyprogesterone Acetate (JMF-M) in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Hellenic Cooperative Oncology Group Study

Contact Info

Product

Resources

About